Close Menu

This story has been updated with additional information from Abbott's earnings call. 

NEW YORK – Abbott on Thursday said that its Diagnostics business revenues grew 5 percent year over year in the second quarter, while its total revenues were down 8 percent.

For the three months ended June 30, the Abbott Park, Illinois-based firm reported overall Q2 revenues of $7.33 billion, down from $7.98 billion in Q2 2019, and down 5 percent on an organic basis. The company beat the consensus Wall Street estimate of $6.75 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.